Auauniversity

Update Series (2023) Lesson 33: A Critical Appraisal of the 2021 AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23

Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer At the conclusion of these activities, participants will be able to: 1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer. 2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics). 3. Understand opportunities to improve quality and compliance with ADT treatment across different treatment populations. 4. Appreciate financial challenges that may be associated with current therapy options for advanced prostate cancer. 5. Apply treatment approaches that improve patient adherence to ADT including use of oral and parenteral therapies. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Myovant Sciences LTD Pfizer, Inc. REFERENCES: Benjamin, D.J., Shrestha, A., Fellman, D. et al. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from t

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects CME Available: https://auau.auanet.org/node/39087 At the conclusion of these activities, participants will be able to: 1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy. 2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk. 3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments. 4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics. 5. Review management options for adverse effects of newer agents for advanced prostate cancer. This series is supported by independent educational grants from:  Myovant Sciences LTD Pfizer, Inc. REFERENCES: 1. Association of androgen deprivation therapy with cardiovascular d

Genetic Testing and Stone Disease Co-host: Kyle Wood, MD Population analysis demonstrated that genetic conditions resulting in stone disease are magnitudes higher than those seen in clinical cohorts, suggesting underdiagnosis. Urologist play a unique role as we often times have many touch points with these patient given their presentation for stone disease. With the advancement of treatments, specifically in primary hyperoxaluria, it is essential that urologist play a more active role in the earlier diagnosis of patients. Genetic testing has become readily available at lower cost and much of the perceived barriers to genetic testing are addressed by current available programs. Outline: 1. The contribution of genetics to kidney stone disease 2. Specific studies using genetic testing 3. Primary Hyperoxaluria as an example 4. Current Genetic Testing and Ease 5. The role of the Urologist References: - Hill AJ, Basourakos SP, Lewicki P, et al. Incidence of kidney stones in the United States: The Continuous N

Advances in ADT Part II: A Guide for Urologists CME Available: https://auau.auanet.org/node/39385 LEARNING OBJECTIVES After participating in this educational activity, participants will be able to: 1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC. 2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer. 3. Facilitate discussions with patients and caregivers regarding treatment intensification for advanced prostate cancer. 4. Identify the role of combination therapy with ADT and additional systemic therapy to yield optimal survival outcomes for metastatic prostate cancer. 5. Differentiate mechanisms of action and side effects when ADT is delivered via GnRH agonists vs. antagonists. ACKNOWLEDGEMENTS Independent educational grant support provided by: Myovant Sciences LTD Pfizer, Inc.

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice CME Available: https://auau.auanet.org/node/39292 After participating in this educational activity, participants will be able to: 1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline. 2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer. 3. Define M0 CRPC and the treatment options. 4. Identify clinically meaningful endpoints in clinical trials of patients with M0 CRPC. 5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC. 6. Discuss treatment intensification in mHSPC. 7. Discuss challenges in incorporating AUA/SUO Advanced Prostate Cancer Guideline and management of advanced mHSPC and CRPC into community practice. ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: • Astellas and Pfizer, Inc. • Janssen Biotech, Inc., administered by Janssen Scientific Affai

AUA2023 Medical Student Forum

AUA2023: Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide CME Available: https://auau.auanet.org/node/38322 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/38312 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

Treatment for Hormone Sensitive Prostate Cancer CME Available: https://auau.auanet.org/node/38703 Treatment for Hormone Sensitive Prostate Cancer (2023), is an exciting new educational offering to update urologists on the latest advancements in the management of hormone sensitive prostate cancer (HSPC), including treatment intensification. This educational initiative is comprised of multiple formats, including a live virtual course, on-demand webcast, and a podcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion. At the conclusion of this activity, participants will be able to: 1. Apply the AUA Clinical Guidelines for Advanced Prostate Cancer for the treatment of HSPC. 2. Summarize the current utilization of treatment intensification in HSCP and apply appropriate treatment intensification in men with HSPC. 3. Describe the current indications, potential benefits and adverse events that may occur with use of doublet and

Update Series (2023) Lesson 21: Management of Chronic Pelvic Pain in Men Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23

AUA2023: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider CME Available: https://auau.auanet.org/node/38307 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation CME Available: https://auau.auanet.org/node/38327 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Merck & Co., Inc. Pfizer, Inc.

AUA2023: What the General Urologist Should Know about Care of Transgender Patients CME Available: https://auau.auanet.org/node/38342 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: Refractory Overactive Bladder: How To Select 3rd Line Therapies and Optimize Outcomes CME Available: https://auau.auanet.org/node/38287 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas Urovant Sciences, Inc.

AUA2023: Prostate Cancer Diagnosis CME Available: https://auau.auanet.org/node/38302 CME Expiration Date: May, 2024 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed. CME Available: https://auau.auanet.org/node/38615 ACKNOWLEDGEMENTS This educational series is supported by an independent educational grant from AstraZeneca. After participating in this educational series, participants will be able to: 1. Delineate key factors to risk stratify patients with NMIBC and MIBC. 2. Review guidelines f

AUA2023: Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women CME Available: https://auau.auanet.org/node/38337/ ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.

AUA2023: Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice CME Available: https://auau.auanet.org/node/38317 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.

AUA2023: AUA Guidelines on Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/38297 ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.